MYSELF

DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 36Yrs Exp. in the feld of Organic Chemistry,Working for AFRICURE PHARMA as ADVISOR earlier with GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, NO ADVERTISEMENTS , ACADEMIC , NON COMMERCIAL SITE, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution, ........amcrasto@gmail.com..........+91 9323115463, Skype amcrasto64

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Indian Biosimilars Market

June 17, 2014 3:43 am / Leave a comment

Indian Biosimilars Market

India is one of the biggest sources of generic industry and is one of the emerging markets with its high population and investment in technology. Although India does not have stringent regulations, the country has a big potential for biosimilars…

If we have a look at the sales figures of Indian biosimilars, 200 million US dollars of sales was recorded in 2008. But according to the analysts, the market will grow to 580 mUSD in 2012, which means a CAGR +30%.

http://www.biosimilarnews.com/indian-biosimilars-market

World’s first biosimilar antibody is approved in Korea

June 17, 2014 3:39 am / Leave a comment

celltrion Worlds first biosimilar antibody* is approved in Korea

South Korean biosimilar manufacturer Celltrion, today declared that, Korean Food and Drug Administration approved its first biosimilar monoclonal antibody, Remsima.

Remsima is a biosimilar version of Remicade, the blockbuster in Rheumatoid Arthitis (RA). Korean FDA approved the product in several indications including RA, ankylosing spondylitis, ulcerative colitis, psoriasis and Crohn’s disease.

http://www.biosimilarnews.com/worlds-first-biosimilar-antibody-is-approved-in-korea

Oncobiologics launches Phase I clinical trial for Humira biosimilar ONS 3010

June 17, 2014 3:31 am / Leave a comment

Oncobiologics launches Phase I clinical trial for Humira biosimilar:ONS 3010

Oncobiologics, Inc. announced that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version… READ MORE

http://www.biosimilarnews.com/oncobiologics-launches-phase-i-clinical-trial-for-humira-biosimilar?utm_source=Biosimilar%20News%20%7C%20Newsletter&utm_campaign=5c2d4bbf24-16_06_2014_Biosimilar_News&utm_medium=email&utm_term=0_9887459b7e-5c2d4bbf24-335885197

How leptin, the ‘satiety hormone,’ reverses diabetes

June 17, 2014 1:14 am / Leave a comment

Lyra Nara Blog

Treatment with leptin, the hormone associated with fullness or satiety, reverses hyperglycemia in animals models of poorly controlled type 1 (T1D) and type 2 (T2D) diabetes by suppressing the neuroendocrine pathways that cause blood glucose levels to soar, a Yale-led team of researchers has found. The study appears in the Advance Online Publication of Nature Medicine.

The leptin hormone regulates metabolism, appetite, and body weight. The researchers discovered that, in a fasting state, rats with poorly controlled T1D and T2D diabetes had lower plasma insulin and leptin concentrations and large increases in concentrations of plasma corticosterone—a stress hormone made in the adrenal glands that raises levels of blood glucose.

The researchers then found that normalizing plasma leptin concentrations in the T1D rats with a leptin infusion resulted in marked reductions in plasma glucose concentrations, which could mostly be attributed to reduction in rates of liver conversion of…

View original post 180 more words

New discoveries could help neutralize chemical weapons

June 17, 2014 1:13 am / Leave a comment

Lyra Nara Blog

University of Tennessee discoveries could help neutralize chemical weapons

In this image, the nerve agent sarin is bound to a bioscavenger enzyme. Credit: Jeremy Smith

Researchers at the University of Tennessee, Knoxville, are a step closer to creating a prophylactic drug that would neutralize the deadly effects of the chemical weapons used in Syria and elsewhere.

Jeremy Smith, UT-ORNL Governor’s Chair and an expert in computational biology, is part of the team that is trying to engineer enzymes—called bioscavengers—so they work more efficiently against chemical weapons. The work is a joint effort between scientists at UT, Oak Ridge National Laboratory and a French national laboratory in Grenoble. Their study was published recently in the Journal of Physical Chemistry.

Nerve agents, such as sarin, are among the most highly toxic chemical weapons. The study focuses on engineering enzymes that catalyze the hydrolysis of nerve agents as a prophylactic approach to diminishing their toxic effects.

“Enzymes exist that can…

View original post 311 more words

‘Onion’ vesicles for drug delivery developed

June 17, 2014 1:13 am / Leave a comment

Lyra Nara Blog

'Onion' vesicles for drug delivery developed

Black and white CryoTEM images of the vesicles were turned into colorized 3-D models to better show their layers. Credit: University of Pennsylvania

One of the defining features of cells is their membranes. Each cell’s repository of DNA and protein-making machinery must be kept stable and secure from invaders and toxins. Scientists have attempted to replicate these properties, but, despite decades of research, even the most basic membrane structures, known as vesicles, still face many problems when made in the lab. They are difficult to make at consistent sizes and lack the stability of their biological counterparts.

Now, University of Pennsylvania researchers have shown that a certain kind of dendrimer, a molecule that features tree-like branches, offers a simple way of creating vesicles and tailoring their diameter and thickness. Moreover, these dendrimer-based vesicles self-assemble with concentric layers of membranes, much like an onion.

By altering the concentration of the dendrimers…

View original post 974 more words

DR RAFI….2024: Biosimilars 10 years from now…….http://blog.bioinfomedical.com/

June 16, 2014 12:00 pm / 1 Comment on DR RAFI….2024: Biosimilars 10 years from now…….http://blog.bioinfomedical.com/

The worldwide biologics market was 160 billion dollars in 2012. Half of this was from US sales..READ ALL AT

http://blog.bioinfomedical.com/2024-biosimilars-10-years-from-now/

ABOUT AUTHOR OF THE BLOGPOST

Dr. Rafael "Rafi" Boritzer

Current	ThinkTech Hawaii, Bioinfomedical Ltd. / InfoMedical L.L.C.http://www.linkedin.com/in/doctorboritzer

www.linkedin.com/in/doctorboritzer LINKEDIN

http://blog.bioinfomedical.com/ BLOG

Chairman of the Board of Directors

Bioinfomedical Ltd. / InfoMedical L.L.C.

Started and built entrepreneurial venture that began as a consulting firm and grew into a successful business engaged in the global transfer of medical/gerontological technologies and software, marketing of research cytokines, and strategic alliances with bio-similar producers. Fostered relationships in Hawaii, Central/Southeast Asia, Oceania, Central Europe, Middle East, and East Africa, to accelerate growth of the business and further its objectives. Created differentiation strategies designed to cope with competitive marketing pressures primarily in long-term healthcare, specialty medical institutions and pharmaceutical distributors in the U.S. and Southeast Asia.

ABOUT HIM BY HIM

Over the course of my 20+ year career as an interdisciplinary and multicultural university educator, social scientist, marketer, entrepreneur and administrator, I have directed organizations, programs and initiatives that promote academic excellence, improve student performance, and strengthen educational outcomes. I have taught at Professor levels in the disciplines of healthcare administration, healthcare management information systems, sociology, global marketing and more. I have a track record in leading and participating in accreditation requirements, and in driving the design and development of curriculum and course offerings, at both graduate and undergraduate levels. My international experience encompasses five continents and I have an in-depth understanding of geopolitical contexts of business and effects on global and local economy and education.

Complementing my teaching and administrative background is executive and research experience in healthcare, geriatrics, entrepreneurship, and marketing, including the conceptualization, startup, and growth of a successful firm engaged in the global transfer of medical/gerontological technologies and software, marketing of research cytokines, and strategic alliances. InfoMedical Biotechnology (www.bioinfomedical.com) satisfies customers’ demand for high quality cytokine products. The use of medical diagnostics is growing in importance, as bigger proportion of the world’s population age and the cost of healthcare continues to rise. The company provides scientists with tools to investigate the genetic and molecular basis for human development and disease; knowledge that is applied in development, discovery and manufacture of new drugs.

Specialties: Education Program Development; Teaching; Student Recruitment-Retention; Distance Learning Modalities; Research & funding; Community Health; Sustainable Entrepreneurship; Strategic Planning; Sociology; Disruptive Innovation; and Global Business Strategies.

Knowledge-based approaches to co-crystal design

June 16, 2014 8:04 am / 1 Comment on Knowledge-based approaches to co-crystal design

Knowledge-based approaches to co-crystal design – CrystEngComm (RSC Publishing) //

The use of knowledge-based methods has been intimately connected with the field of co-crystal design since the seminal papers of Etter and Desiraju in the 1990s. Here we explain and exemplify how rational co-crystal design has been carried out in the past using crystal structure knowledge as well as presenting emerging methodologies for knowledge-based co-former selection.

Graphical abstract: Knowledge-based approaches to co-crystal design

Peter A. Wood, Neil Feeder, Matthew Furlow, Peter T. A. Galek, Colin R. Groom and Elna Pidcock

CrystEngComm, 2014, 16, 5839 DOI:10.1039/C4CE00316K

http://pubs.rsc.org/en/Content/ArticleLanding/2014/CE/C4CE00316K?utm_medium=email&utm_campaign=pub-CE-vol-16-issue-26&utm_source=toc-alert#!divAbstract

Knowledge-based approaches to co-crystal design – CrystEngComm (RSC Publishing) //

Knowledge-based approaches to co-crystal design

Peter A. Wood,*^a Neil Feeder,^a Matthew Furlow,^a Peter T. A. Galek,^a Colin R. Groom^a and Elna Pidcock^a

*Corresponding authors

^aCambridge Crystallographic Data Centre, 12 Union Road, Cambridge, UK

E-mail: wood@ccdc.cam.ac.uk ;
Tel: +44 (0)1223 336408

CrystEngComm, 2014,16, 5839-5848

DOI: 10.1039/C4CE00316K

read at

http://pubs.rsc.org/en/Content/ArticleLanding/2014/CE/C4CE00316K?utm_medium=email&utm_campaign=pub-CE-vol-16-issue-26&utm_source=toc-alert#!divAbstract

FDA Approves Incruse Ellipta…(Med-Chemist)

June 16, 2014 7:40 am / Leave a comment

read at

http://www.med-chemist.com/2014/06/fda-approves-incruse-ellipta.html

GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. – See more at: http://www.med-chemist.com/2014/06/fda-approves-incruse-ellipta.html#sthash.yVleIn3C.dpuf

FDA Approves Entyvio (vedolizumab) to treat Ulcerative Colitis and Crohn’s Disease

June 16, 2014 7:36 am / Leave a comment

Syn-Org-Chemist

FDA Approves Entyvio (vedolizumab) to treat Ulcerative Colitis and Crohn’s Disease.

View original post

Latest Posts

Laporolimus
Laporolimus Rapamycin, 42-cyclohexanecarboxylate CAS 1504576-27-5 MF C58H89NO14 MW 1024.3 g/mol [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] cyclohexanecarboxylate (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexylcyclohexanecarboxylateimmunosuppressant, CRC-015, CRC 015, F5041W3RVA, Rapamycin, 42-cyclohexanecarboxylate Laporolimus is an experimental immunosuppressant compound that…
Lanoracopan
Lanoracopan CAS 2797066-85-2 MFC27H32N2O4 MW448.6 g/mol 4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid Benzoic acid, 4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]- 4-{(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acidcomplement factor B inhibitor, MY 008211A, Factor B-IN-5, Y5UN7AE8SF Lanoracopan (also known by its…
Lanisidenib
Lanisidenib Cas 2135537-20-9 MF C28H23ClF3N5O4S MW618.03 g/mol (3S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-1,1-dioxo-1,2-thiazolidine-3-carboxamide IUPAC Name: (3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3, 3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo-1λ⁶,2-thiazolidine-3-carboxamide 3-Isothiazolidinecarboxamide, N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-, 1,1-dioxide, (3S)- (3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo1λ6,2-thiazolidine-3-carboxamideisocitrate dehydrogenase inhibitor, antineoplastic, G5J396CG5J Lanisidenib is a potent,…
Itareparib
Itareparib CAS 1606995-47-4 MF C20H26FN3O2 MW359.4 g/mol 2-(1-Cyclohexyl-4-piperidinyl)-6-fluoro-2,3-dihydro-3-oxo-1H-isoindole-4-carboxamide 1H-ISOINDOLE-4-CARBOXAMIDE, 2-(1-CYCLOHEXYL-4-PIPERIDINYL)-6-FLUORO-2,3-DIHYDRO-3-OXO- 2-(1-cyclohexylpiperidin-4-yl)-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole4-carboxamidepoly (ADP-ribose) polymerase (PARP) inhibitor, antineoplastic, NMS-03305293, NMS-293, NMS 03305293, NMS 293, KFI1190L8L, NV 578, Itareparib…
Irodanoprost
Irodanoprost CAS 2055490-48-5 MF C34H44F2N2O13P2 MW788.7 g/mol 7-[(2R)-2-[(E,3R)-4,4-difluoro-3-[2-[4-[(4-hydroxy-4,4-diphosphonobutyl)carbamoyl]phenyl]acetyl]oxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid (2R)-2-[(1E,3R)-4,4-Difluoro-3-[[2-[4-[[(4-hydroxy-4,4-diphosphonobutyl)amino]carbonyl]phenyl]acetyl]oxy]-4-phenyl-1-buten-1-yl]-5-oxo-1-pyrrolidineheptanoic acid 7-[(2R)-2-{(1E,3R)-4,4-difluoro-3-[({4-[(4-hydroxy-4,4-diphosphonobutyl)carbamoyl]phenyl}acetyl)oxy]-4-phenylbut-1-en-1-yl}-5-oxopyrrolidin-1-yl]heptanoic acidprostaglandin receptor agonist, osteogenesis-related diseases, KP8BK46Z6R, MES 1022 Irodanoprost (also known as MES-1022) is…
Inidascamine
Inidascamine CAS 903884-71-9 MF C12H17N3O2 MW235.28 g/mol (-)-(2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one (2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-oneschizophrenia, 3LW01V88B7, RL 007 Inidascamine (developmental code name RL-007 or FSV7-007) is an experimental, orally administered drug…
Imofinostat
Imofinostat CAS 1338320-94-7 MF C17H16N2O4S MW 344.4 g/mol (2E)-3-[1-(benzenesulfonyl)-2,3-dihydro-1H-indol-5-yl]-N-hydroxyprop2-enamidehistone deacetylase inhibitor, antineoplastic, ABT-301, MPT0E028, ABT 301, MPT0E 028, T65L58FI65 Imofinostat (also known as ABT-301 or MPT0E028)…
Ifupinostat
Ifupinostat CAS 1235449-52-1 MF C23H25N9O3S MW507.6 g/mol N-hydroxy-2-[methyl-[[2-[6-(methylamino)-3-pyridinyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide 5-Pyrimidinecarboxamide, N-hydroxy-2-(methyl((2-(6-(methylamino)-3-pyridinyl)-4-(4-morpholinyl)thieno(3,2-d)pyrimidin-6-yl)methyl)amino)- DQ7TD3X4ZJ, BEBT908 FREE BASE, Ifupinostat (brand name Betlin; formerly known as BEBT-908) is a first-in-class, dual-action…
Gozanertinib
Gozanertinib CAS 1226549-49-0 MF C32H31N5O3 MW533.6 g/mol (E)-4-(dimethylamino)-N-[3-[4-[[(1S)-2-hydroxy-1-phenylethyl]amino]-6-phenylfuro[2,3-d]pyrimidin-5-yl]phenyl]but-2-enamide (2E)-4-(dimethylamino)-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]but-2-enamideepidermal growth factor receptor tyrosine kinase inhibitor, antineoplastic, DBPR 112, ABT 101, 6G0COS33K4 Gozanertinib (also known as DBPR112…
Gintemetostat
Gintemetostat (1S)-1-[(3R)-3-amino-4′-[(6-amino-9H-purin-9-yl)methyl]-6′-(2,5-difluoro-4-methoxyphenyl)-3,4,5,6-tetrahydro-2H-[1,3′-bipyridin]-3-yl]-2,2-difluoroethan1-olantineoplastic, KTX 1001, NSD2 inhibitor 161, A48CGJ5UQM CAS 2604513-16-6 MF C25H26F4N8O2 MW 546.5 g/mol (S)-1-((R)-3-Amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol Gintemetostat (also known as KTX-1001) is a first-in-class, orally administered…

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP

Blog at WordPress.com.

	shivkr2 on SPSR Excellence Award 2025 – S…
	Bonkasaurus on Infigratinib phosphate
	PALOVAROTENE \| ORGAN… on Palovarotene
	Pfizer just purchase… on Temanogrel
	Pfizer To Cash In On… on Temanogrel
	VÍDEOS – A Pfizer ac… on Temanogrel
	Pfizer Bought Arena… on Temanogrel
	Pfizer va profita de… on Temanogrel
	Pfizer to Cash In on… on Temanogrel
	Pfizer tocmai a achi… on Temanogrel
	Pfizer just purchase… on Temanogrel
	Pfizer just purchase… on Temanogrel
	Tanya A on Dasotraline, ダソトラリン
	Julia Chernus on RIDINILAZOLE
	Adv.Siji Antony Kera… on Myself Anthony Crasto up for g…

SEARCH THIS BLOG

FLAGS AND HITS

Meta

Pages

Archives

Categories

MYSELF

Follow Blog via Email

Verified Services

Recent Posts

SEARCH THIS BLOG

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Dr. Rafael “Rafi” Boritzer

Share this:

Knowledge-based approaches to co-crystal design

Share this:

Share this:

Share this:

Post navigation

SEARCH THIS BLOG

DR ANTHONY MELVIN CRASTO

Meta

Follow Blog via Email

ORGANIC SPECTROSCOPY

Latest Posts

Pages

feedjit

Recent Comments

DISCLAIMER

SEARCH THIS BLOG

SEARCH THIS BLOG

FLAGS AND HITS

Follow Blog via Email